References

REFERENCES

1. J. C. Presti, Jr., J. J. Chang, V. Bhargava, et al., The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol, 163 (2000), 163-7.
   
2. K. Roehl, J. Antenor, W. Catalona, Serial biopsy results in prostate cancer screening study. J Urol, 167 (2002), 2435-9.
   
3. T. M. Koppie, F. J. Bianco, Jr., K. Kuroiwa, et al., The clinical features of anterior prostate cancers. BJU Int, 98 (2006), 1167-71.
   
4. D. Beyersdorff, M. Taupitz, B. Winkelmann, et al., Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology, 224 (2002), 701-6.
   
5. M. Mullerad, H. Hricak, K. Kuroiwa, et al., Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol, 174 (2005), 2158-63.
   
6. H. Hricak, S. White, D. Vigneron, et al., Carcinoma of the prostate gland: MR imaging with pelvic phased array coil versus integrated endorectal-pelvic phased-array coils. Radiology, 193 (1994), 703-9.
   
7. O. Akin, E. Sala, C. S. Moskowitz, et al., Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology, 239 (2006), 784-92.
   
8. M. Schnall, H. M. Pollack, Magnetic resonance imaging of the prostate. Urol Radiol, 12 (1990), 109-14.
   
9. I. Kaplan, N. E. Oldenburg, P. Meskell, et al., Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging, 20 (2002), 295-9.
   
10. M. R. Cooperberg, D. P. Lubeck, M. V. Meng, et al., The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol, 22 (2004), 2141-9.
    
11. G. Draisma, R. Boer, S. J. Otto, et al., Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst, 95 (2003), 868-78.
    
12. R. Etzioni, D. F. Penson, J. M. Legler, et al., Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94 (2002), 981-90.
    
13. M. I. Patel, D. T. DeConcini, E. Lopez-Corona, et al., An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol, 171 (2004), 1520-4.
    
14. M. W. Kattan, J. A. Eastham, A. M. Stapleton, et al., A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90 (1998), 766-71.
    
15. M. W. Kattan, A. M. Stapleton, T. M. Wheeler, et al., Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer, 79 (1997), 528-37.
    
16. A. J. Stephenson, P. T. Scardino, J. A. Eastham, et al., Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst, 98 (2006), 715-17.
    
17. H. B. Carter, J. Sauvageot, P. C. Walsh, et al., Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol, 157 (1997), 2206-9.
    
18. J. I. Epstein, D. W. Chan, L. J. Sokoll, et al., Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol, 160 (1998), 2407.
    
19. J. I. Epstein, H. Sanderson, H. B. Carter, et al., Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology, 66 (2005), 356-60.
    
20. J. I. Epstein, P. C. Walsh, M. Carmichael, et al., Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA, 271 (1994), 368-74.
    
21. Y. Goto, M. Ohori, A. Arakawa, et al., Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol, 156 (1996), 1059-63.
    
22. M. W. Kattan, J. A. Eastham, T. M. Wheeler, et al., Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol, 170 (2003), 1792-7.
    
23. A. W. Partin, M. W. Kattan, E. N. Subong, et al., Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA, 277 (1997), 1445-51.
    
24. A. Shukla-Dave, H. Hricak, M. W. Kattan, et al., The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int, 99 (2007), 786-93.
    
25. F. V. Coakley, J. Kurhanewicz, Y. Lu, et al., Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology, 223 (2002), 91-7.
    
26. H. Hricak, MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol, 78 (2005), S103-S111.
    
27. K. K. Yu, J. Scheidler, H. Hricak, et al., Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology, 213 (1999), 481-8.
    
28. F. Cornud, T. Flam, L. Chauveinc, et al., Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology, 224 (2002), 203-10.
    
29. M. R. Engelbrecht, G. J. Jager, R. J. Laheij, et al., Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol, 12 (2002), 2294-302.
    
30. F. May, T. Treumann, P. Dettmar, et al., Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int, 87 (2001), 66-9.
    
31. M. Mullerad, H. Hricak, L. Wang, et al., Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology, 232 (2004), 140-6.
    
32. E. K. Outwater, R. O. Petersen, E. S. Siegelman, et al., Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology, 193 (1994), 333-9.
    
33. M. D. Rifkin, E. A. Zerhouni, C. A. Gatsonis, et al., Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med, 323 (1990), 621-6.
    
34. L. Wang, H. Hricak, M. W. Kattan, et al., Prediction of prostate cancer organ-confined disease: the incremental value of endorectal coil magnetic resonance imaging to partin staging nomograms (2001 version). Radiology, 238 (2006), 597-603.
    
35. L. Wang, J. Zhang, L. H. Schwartz, et al., Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology, 242 (2007), 182-8.
    
36. L. Wang, M. Mullerad, H. N. Chen, et al., Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology, 232 (2004), 133-9.
    
37. H. Hracik, L. Wang, D. C. Wei, et al., The role of preoperative endorectal magnetic imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer, 100:12 (2004), 2655-63.
    
38. J. A. Eastham, P. T. Scardino, Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology, 2nd edn., eds. N. J. Vogelzand, P. T. Scardino, W. U. Shipley, et al. Philadelphia: Lippincott Williams & Wilkins, 2000; 722-38.
    
39. F. V. Coakley, S. Eberhardt, D. C. Wei, et al., Blood loss during radical retropubic prostatectomy: relationship to morphologic features on preoperative endorectal magnetic resonance imaging. Urology, 59 (2002), 884-8.
    
40. F. V. Coakley, S. Eberhardt, M. W. Kattan, et al., Urinary continence after radical retropubic prostatectomy: relationship with membranous urethral length on preoperative endorectal magnetic resonance imaging. J Urol, 168 (2002), 1032-5.
    
41. L. Wang, H. Hricak, M. W. Kattan, et al., Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol, 186 (2006), 743-8.
    
42. E. Sala, S. C. Eberhardt, O. Akin, et al., Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology, 238 (2006), 176-83.
    
43. D. Pucar, A. Shukla-Dave, H. Hricak, et al., Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology, 236 (2005), 545-53.
    
44. D. Pucar, H. Hricak, A. Shukla-Dave, et al., Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys, 69 (2007), 62-9.
    
45. T. Sella, L. H. Schwartz, P. W. Swindle, et al., Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology, 231 (2004), 379-85.
    
46. J. M. Silverman, T. L. Krebs, MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol, 168 (1997), 379-85.
    
47. A. K. Leventis, S. F. Shariat, K. M. Slawin, Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology, 219 (2001), 432-9.
    
48. J. Mohler, R. J. Babaian, R. R. Bahnson, et al., NCCN Clinical Practice Guidelines in Oncology Prostate Cancer, v 1.2007. In National Comprehensive Cancer Network, 2007.
    
49. E. S. Amis, Jr., L. R. Bigongiari, E. I. Bluth, et al., Pretreatment staging of clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology, 215 Suppl (2000), 703-8.
    
50. M. Fuchsjager, A. Shukla-Dave, O. Akin, et al., Prostate cancer imaging. Acta Radiol, 49:1 (2008), 107-20.
    
51. M. G. Harisinghani, J. Barentsz, P. F. Hahn, et al., Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N Engl J Med, 348:25 (2003), 2491-9. Erratum in: N Engl J Med, 349:10 (2003), 1010.
    
52. R. A. Heesakkers, J. J. Futterer, A. M. Hovels, et al., Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR imaging at 1.5 and 3.0 T: early experience. Radiology, 239 (2006), 481-7. 53. M. L. Cher, F. J. Bianco, Jr., J. S. Lam, et al., Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol, 160 (1998), 1387-91.
    
53. Z. A. Dotan, F. J. Bianco, Jr., F. Rabbani, et al., Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol, 23 (2005), 1962-8.
    
54. G. M. Freedman, W. G. Negendank, G. R. Hudes, et al., Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer. Urology, 54 (1999), 118-23.
    
55. D. I. Rosenthal, Radiologic diagnosis of bone metastases. Cancer, 80 (1997), 1595-607.
    
56. N. Ghanem, M. Uhl, I. Brink, et al., Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol, 55:1 (2005), 41-55.
    
57. F. E. Lecouvet, D. Geukens, A. Stainier, et al., Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol, 25 (2007), 3281-7.
    
58. H. Hricak, P. L. Choyke, S. C. Eberhardt, et al., Imaging prostate cancer: a multidisciplinary perspective. Radiology, 243 (2007), 28-53.
    
59. H. Schoder, K. Herrmann, M. Gonen, et al., 2-[¹⁸ F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res, 11 (2005), 4761-9.
    
60. H. A. Macapinlac, J. L. Humm, T. Akhurst, et al., Differential metabolism and pharmacokinetics of l-[1-¹¹ C]-methionine and 2-[¹⁸ F] fluoro-2- deoxyglucose (FDG) in androgen independent prostate cancer. Clin Positron Imaging, 2 (1999), 173-81.
    
61. P. L. Jager, W. Vaalburg, J. Pruim, et al., Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med, 42 (2001), 432-45.
    
62. R. Nunez, H. A. Macapinlac, H. W. Yeung, et al., Combined ¹⁸ F-FDG and ¹¹ C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med, 43 (2002), 46-55.
    
63. N. H. Bander, Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol, 3 (2006), 216-25.
    
64. J. J. Pollen, K. S. Witztum, W. L. Ashburn, The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol, 142 (1984), 773-6.
    
65. J. A. Schneider, C. R. Divgi, A. M. Scott, et al., Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med, 35 (1994), 1748-52.
    
66. H. Yeung, H. Schoder, S. Larson, Utility of PET/CT for assessing equivocal PET lesions in oncology-initial experience [abstract]. J Nucl Med, 43 (2007), 32p.
    
67. F. Dehdashti, J. Picus, J. M. Michalski, et al., Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging, 32 (2005), 344-50.
    
68. S. M. Larson, M. Morris, I. Gunther, et al., Tumor localization of 16beta-F-fluoro-5alpha-dihydrotestosterone versus F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med, 45 (2004), 366-73.
    
69. M. Imbriaco, S. M. Larson, H. W. Yeung, et al., A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res, 4 (1998), 1765-72.
    
70. P. Sabbatini, S. M. Larson, A. Kremer, et al., Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol, 17 (1999), 948-57.
    
71. M. J. Morris, T. Akhurst, S. M. Larson, et al., Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res, 11 (2005), 3210-16.